The Ramelius Resources Ltd (ASX: RMS) share price is in focus today after the miner reported September quarter gold production of 48,839 ounces and underlying free cash flow of A$60.2 million.

What did Ramelius Resources report?

• Gold production: 48,839 ounces
• FY27 production guidance: 205,000 – 225,000 ounces
• Underlying free cash flow: A$60.2 million
• Cash and gold balance: A$768 million (up from A$649.6 million at 30 June 2026)
• Ore stockpile: 27,680 tonnes at 4.78 g/t (4,254 contained ounces)
• Ongoing A$250 million share buyback, with A$18 million completed in the quarter

What else do investors need to know?

Production was slightly impacted by wet weather in September, delaying haulage from the high-grade Penny mine, but haulage has now recommenced. The company remains confident in achieving its full-year gold production guidance.

Ramelius continues to advance its growth projects, including the Mt Magnet mill expansion, with installation underway on a new crusher and gravity tower. The Rebecca-Roe project received a key environmental Works Approval during the quarter, moving it closer to full approval.

The sale of Edna May was completed for A$300 million, boosting the company’s financial position and enabling continued investment in expansion and exploration.

What did Ramelius Resources management say?

Managing Director Mark Zeptner said:

We continue to build on the strong momentum from last financial year particularly with Dalgaranga ramping up tonnages, commissioning the new paste plant and continuing to out-perform on grade and recovery expectations. We are excited to see construction activities taking place on the Mt Magnet mill expansion and are bringing forward some capital expenditure at Rebecca-Roe as we near finalisation of all required approvals.

What’s next for Ramelius Resources?

Ramelius is set to progress its 4-year growth strategy targeting more than 600,000 ounces of gold production by FY30. The recent resource upgrades and project approvals back its plan for sustained output through to the late 2030s.

With a strong balance sheet, ongoing buybacks, and an active exploration program, Ramelius aims to displace lower-grade material and maximise output at key sites, focusing on discovery and development opportunities.

Ramelius Resources share price snapshot

Over the past 12 months, Ramelius Resources shares have declined 8%, trailing the S&P/ASX 200 Index (ASX: XJO), which has declined 2% over the same period.

View Original Announcement

The post Ramelius Resources September quarter earnings: Gold production update and outlook appeared first on The Motley Fool Australia.

More reading

• 6 ASX shares set to soar 39% to 135%
• 3 ASX shares given buy ratings this week offering 20% to 40% upside
• 5 ASX 200 shares upgraded by experts this week
• Here are the top 10 ASX 200 shares today
• Here are the top 10 ASX 200 shares today

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

ASX passive income shares are some of my favourite stocks to buy because they pay real cash flow into our bank accounts. Some of them have incredibly high dividend yields.

Uncertainty in the wider economy and higher interest rates have pushed share prices lower and, in turn, sent dividend yields higher.

With that in mind, there are a few high-yield names that come to mind, and the two below are among the most attractive.

Charter Hall Long WALE REIT (ASX: CLW)

The first business I want to highlight is this real estate investment trust (REIT), which has a highly diversified portfolio spanning sectors such as service stations, hotels, office buildings, Bunnings properties, and distribution centres.

Higher interest rates are particularly a headwind for REITs because they increase the cost of debt (which REITs tend to have), and it’s a headwind for property valuations. But I don’t expect interest rates to stay this high forever, meaning that this is a useful time to invest.

The Charter Hall Long WALE REIT unit price has dropped 24% in the past year (at the time of writing), but I don’t think the underlying business is worth 24% less than it was before.

It has several positive factors, including a weighted average lease expiry (WALE) of around 9 years, which provides long-term rental income security. That rent is regularly growing thanks to a mixture of fixed annual increases and inflation-linked increases.

The business plans to maintain its annual distribution at 25.5 cents per unit in FY27, which translates into a forward distribution yield of 8.4%.

WAM Microcap Ltd (ASX: WMI)

This listed investment company (LIC) is the other ASX passive income share idea that I want to highlight with a huge dividend yield.

LICs are a great structure because they allow investors to gain exposure to a portfolio of shares and can turn some of the generated investment profits into a steady (or growing) dividend.

WAM Microcap looks to invest in the smallest businesses on the ASX, ones with a market capitalisation under $300 million at the time of investment.

The LIC grew its regular annual dividend each year between FY18 and FY23, maintained it in FY24, and grew it slightly in FY25 and FY26.

Its FY26 annual dividend per share of 10.7 cents translates into a huge grossed-up dividend yield of 11.75%, including franking credits, at the time of writing. While the business only grew its annual dividend by 1% in FY26, any increase is useful when you’re talking about a double-digit yield.

WAM Microcap needs to keep delivering investment returns to grow its dividend, but its current profit reserve covers more than four years of payments at the current level.

$600 of passive income per month

Between the two stocks above, the average dividend yield is around 10%, including franking credits.

To reach $600 per month in income, we should set an annual goal, since they don’t pay monthly. The target is $7,200 per year. For that level of income, an investor would need around $72,000 invested in the two names above.

But I’d suggest spreading investment dollars across additional ASX share ideas that can generate returns, rather than putting too much in just two names.

The post 2 ASX passive income share ideas I’d use to generate $600 a month in 2027 appeared first on The Motley Fool Australia.

More reading

• How much do I need to retire on $85,000 a year at 50?
• 6 ASX REITs just hit 52-week lows. Do any brokers say buy?
• How much do I need to retire on $110,000 a year at 65?
• Where I’d invest in ASX shares after the recent RBA rate rise
• 2 very cheap ASX shares near 52-week lows I’d buy today

Motley Fool contributor Tristan Harrison has positions in Wam Microcap. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Broker UBS has just significantly upgraded its share price target for Telix Pharmaceuticals Ltd (ASX: TLX) after the company announced some positive news this week.

Good news out of the US

Telix said earlier this week that it had been granted fast-track designation by the US Food and Drug Administration for its BiPASS program, which is evaluating a new compound to be used in prostate cancer detection.

BiPASS (Biopsy of the Prostate Avoidance Stratification Study) is evaluating the use of gallium-68 PSMA-PET imaging in combination with MRI for the detection of prostate cancer prior to taking a biopsy.

The company said this week that there was a large clinical need to develop a method to detect the cancer without a biopsy.

Telix said:

Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need, potentially accelerating patient access if approved. More than three million prostate biopsies are performed globally each year, yet up to 75% produce a negative result. Biopsy can be stressful and painful for patients and may provide no meaningful diagnostic benefit, highlighting the importance of improved diagnostic tools earlier in the patient journey.

Broker says the market could be large

UBS said if the BiPASS study is successful, it could expand the total addressable market for Telix’s PSMA compounds by almost 100%.

They said:

Success would establish Telix as first to market in a large new diagnostic indication, a potentially transformative opportunity. We believe the market underappreciates both the commercial upside and probability of success of the BiPASS study.

UBS said its confidence was supported by data from two previous studies and feedback highlighting that there was a strong unmet need and a high likelihood of adoption.

They added:

We believe the FDA New Drug Application pathway and Transitional Pass Through payments could accelerate commercialisation and support higher peak sales than current expectations. We forecast a 10% FY26-FY35 CAGR for Telix’s PSMA-PET franchise versus 6% implied by consensus. If BiPASS is successful, we expect meaningful uptake from FY29, with FDA approval partially de-risked and the recent Fast Track designation encouraging.

UBS said Telix was a rare biotechnology company in that it had a broad, advanced pipeline funded by its established precision medicine business.

They said the company also had a deep therapeutic pipeline supported by the recently announced acquisition of ITM.

UBS raised its price target on Telix shares from $22 to $26, compared with $16.19 at the time of writing.

This would constitute a 60.6% increase if achieved. Telix is valued at $5.24 billion.

The post UBS thinks Telix Pharmaceuticals shares will go how high? appeared first on The Motley Fool Australia.

More reading

• Here are the top 10 ASX 200 shares today
• Telix Pharmaceuticals wins FDA Fast Track for BiPASS prostate cancer imaging
• Buy, hold, sell: Telix Pharmaceuticals, Qualitas, Greatland Resources shares
• These are the 10 most shorted ASX shares
• 2 ASX shares UBS says could increase 13% to 37%

Motley Fool contributor Cameron England has positions in Telix Pharmaceuticals. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Telix Pharmaceuticals. The Motley Fool Australia has recommended Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.